Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 08/25 10:01:42 pm
58.76 USD   +0.29%
08/24 INVESTIGATION F : BMY) over Potential Wrongdoing Announced
08/22 ALLIED MINDS : Given New Debt, Raises Funds For Drug Development
08/21 BRISTOL MYERS S : Fukoku Mutual Life Insurance Co Lowers stake in Br..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : Trademark Application for "MUTAMYCIN" Filed

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/25/2016 | 10:30pm CEST

By a News Reporter-Staff News Editor at Biotech Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "MUTAMYCIN" by Marilyn F. Kelly, representing Bristol-Myers Squibb. This application was made available to the public on August 11, 2016 (see also Pharmaceutical Companies).

The serial number for this application is 73031486.

The international trademark goods and services class code for this trademark application is 005.

As submitted by the applicant, this trademark application relates to the following goods and services: Antibiotic with antitumor activity.

The owner/registrar information for this application is: Marilyn F. Kelly, Bristol-Myers Squibb, Trademark Department, 345 Park Avenue, New York NY 10154.

Keywords for this news article include: Trademarks, Bristol-Myers Squibb, Biotechnology Companies, Biopharmaceutical Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "MUTAMYCIN" Filed
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "FER-IN-SOL" Filed
08/25 BRISTOL MYERS SQUIBB : New Findings from Bristol-Myers Squibb in the Area of Cyc..
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "ENFAMIL FAMILY BEGINNINGS" Fil..
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "MVOKIS" Filed by Bristol-Myers..
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "ENFAMIL AR" Filed
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "TEMPRA" Filed by Bristol-Myers..
08/25 BRISTOL MYERS SQUIBB : An Application for the Trademark "TRI-VI-SOL" Has Been Fi..
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "MEAD JOHNSON NUTRITIONALS" Fil..
08/25 BRISTOL MYERS SQUIBB : An Application for the Trademark "SMART SYMPHONIES" Has B..
More news
Sector news : Pharmaceuticals - NEC
08/25 FTSE retreats as pharma stocks fall
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
08/25DJMylan Boosts Price Assistance for EpiPen Amid Backlash
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 Candidate Clinton's harsh comments on high price of Mylan's EpiPen sends biot..
08/24 When Can Portola's Drug Be Approved, And How Much Does It Matter?
08/23 Game Plan For The Week - Cramer's Mad Money (8/22/16)
08/22 Is The Sky Falling Only On Gilead?
08/19 Play Oncology To Play M&A In Big Pharma?
Advertisement
Financials ($)
Sales 2016 18 890 M
EBIT 2016 4 944 M
Net income 2016 4 379 M
Debt 2016 1 249 M
Yield 2016 2,63%
P/E ratio 2016 22,72
P/E ratio 2017 19,62
EV / Sales 2016 5,26x
EV / Sales 2017 4,78x
Capitalization 98 180 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 68,8 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-14.58%97 896
JOHNSON & JOHNSON15.43%324 776
ROCHE HOLDING LTD.-11.47%217 694
NOVARTIS AG-9.62%213 882
PFIZER INC.7.71%211 206
MERCK & CO., INC.17.99%173 462
More Results